| Budget Amount *help |
¥62,660,000 (Direct Cost: ¥48,200,000、Indirect Cost: ¥14,460,000)
Fiscal Year 2014: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
Fiscal Year 2013: ¥10,140,000 (Direct Cost: ¥7,800,000、Indirect Cost: ¥2,340,000)
Fiscal Year 2012: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2011: ¥10,530,000 (Direct Cost: ¥8,100,000、Indirect Cost: ¥2,430,000)
Fiscal Year 2010: ¥21,710,000 (Direct Cost: ¥16,700,000、Indirect Cost: ¥5,010,000)
|
|---|
| Outline of Final Research Achievements |
Novel specific modulators of various nuclear receptors such as receptors for retinoids, vitamin D, and steroid hormones were developed, and their functions were elucidated. First, novel nuclear receptor ligands bearing a carborane or silyl-/germyl-containing substituents as the hydrophobic pharmacophore were developed. Second, the fluorescent ligands for steroid hormone receptors were synthesized, and their biological functions and fluorescent properties were elucidated. Third, novel derivatives of vitamin K as possible active metabolite were designed and synthesized. Furthermore, the strategies of the research on nuclear receptors were applied to the development of modulators of Store-Operated Calcium Entry (SOCE) and transcriptional cofactor, TAZ. These novel compounds of nuclear receptors and related molecules would be useful for the fundamental research on nuclear receptors and their clinical applications.
|
